{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T14:48:13Z","timestamp":1652626093247},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[1992,1,1]],"date-time":"1992-01-01T00:00:00Z","timestamp":694224000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1992]]},"DOI":"10.1007\/bf00686012","type":"journal-article","created":{"date-parts":[[2004,11,29]],"date-time":"2004-11-29T08:11:43Z","timestamp":1101715903000},"page":"405-408","source":"Crossref","is-referenced-by-count":13,"title":["Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone"],"prefix":"10.1007","volume":"29","author":[{"given":"L.","family":"Thomas Vlasveld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babs G.","family":"Taal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin B. R.","family":"Kroon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten P. W.","family":"Gallee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sjoerd","family":"Rodenhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/978-3-642-81488-4_35","volume":"74","author":"DS Alberts","year":"1980","unstructured":"Alberts DS, Chen H-SG, Chang SY, Peng YM (1980) The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients. Recent Results Cancer Res 74: 293","journal-title":"Recent Results Cancer Res"},{"key":"CR2","first-page":"5874","volume":"48","author":"DS Alberts","year":"1988","unstructured":"Alberts DS, Surwitt EA, Peng Y-M, McCloskey T, Rivest R, Graham V, McDonald L, Roe D (1988) Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. Cancer Res 48: 5874","journal-title":"Cancer Res"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1200\/JCO.1983.1.6.386","volume":"1","author":"KH Antman","year":"1983","unstructured":"Antman KH, Pomfret EA, Aisner J, MacIntyre J, Osteen RT, Greenberger JS (1983) Peritoneal mesothelioma: natural history and response to chemotherapy. J Clin Oncol 1: 386","journal-title":"J Clin Oncol"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0140-6736(85)90526-4","volume":"II","author":"KH Antman","year":"1985","unstructured":"Antman KH, Osteen RT, Klegar KL, Amato DA, Pomfret EA, Larson DA, Corson JM (1985) Early peritoneal mesothelioma: a treatable malignancy. Lancet II: 977","journal-title":"Lancet"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1200\/JCO.1988.6.1.147","volume":"6","author":"K Antman","year":"1988","unstructured":"Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, Lederman G, Corson J (1988) Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965?1985. J Clin Oncol 6: 147","journal-title":"J Clin Oncol"},{"key":"CR6","first-page":"1399","volume-title":"Cancer, principles and practice in oncology","author":"KH Antman","year":"1989","unstructured":"Antman KH, Pass HI, Recht A (1989) Benign and malignant mesothelioma. In: DeVita VT, Hellman S, Rosenberg SIA (eds) Cancer, principles and practice in oncology, 3rd edn. J. B. Lippencott, Philadelphia, p 1399","edition":"3rd edn."},{"key":"CR7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/1097-0142(19870115)59:2<213::AID-CNCR2820590206>3.0.CO;2-I","volume":"59","author":"J-F Bergman","year":"1987","unstructured":"Bergman J-F, Bidart J-M, George M, Beaugrand M, Levy VG, Bohuon C (1987) Elevation of CA 125 in patients with benign and malignant ascites. Cancer 59: 213","journal-title":"Cancer"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0277-5379(88)90119-8","volume":"24","author":"B Bl\u00f6chl-Daum","year":"1988","unstructured":"Bl\u00f6chl-Daum B, Eichler HG, Rainer H, Jakesz R, Salzer H, Steger G, Sch\u00fcller J, G\u00fcnther E, Proksch B, Ehninger G (1988) Escalating dose regimen of intraperitoneal mitoxantrone: phase I study-clinical and pharmacokinetic evaluation. Eur J Cancer Clin Oncol 24: 1133","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/00000478-198908000-00004","volume":"13","author":"DJ Bollinger","year":"1989","unstructured":"Bollinger DJ, Wick MR, Dehner LP, Mills SE, Swanson PE, Clarke RE (1989) Peritoneal malignant mesothelioma versus serous papillary adenocarcinoma ? a histochemical and immunohistochemical comparison. Am J Surg Pathol 13: 659","journal-title":"Am J Surg Pathol"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1200\/JCO.1986.4.7.1135","volume":"4","author":"DE Brenner","year":"1986","unstructured":"Brenner DE (1986) Intraperitoneal chemotherapy: a review. J Clin Oncol 4: 1135","journal-title":"J Clin Oncol"},{"key":"CR11","first-page":"1029","volume":"70","author":"EA Eisenhauer","year":"1986","unstructured":"Eisenhauer EA, Evans WK, Raghavan D, Desmeules MJ, Murray NR, Stuart-Harris R, Wilson KS (1986) Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group study. Cancer Treat Rep 70: 1029","journal-title":"Cancer Treat Rep"},{"key":"CR12","first-page":"203","volume":"2","author":"G Fountzilas","year":"1989","unstructured":"Fountzilas G, Dombros N, Balaskas E, Konstantaras C, Triantafillou A, Kalogera-Fountzila A, Savidis N, Sombolos K, Tourkantonis A (1989) Intraperitoneal chemotherapy with high-dose cisplatin and 5-fluorouracil in patients with advanced ovarian cancer. Reg Cancer Treat 2: 203","journal-title":"Reg Cancer Treat"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1001\/archinte.1980.00330200077024","volume":"140","author":"VC Gandhi","year":"1980","unstructured":"Gandhi VC, Humayun HM, Ing TS, Daugirdas JT, Jablokow VR, Iwatsuki S, Geis P, Hano JE (1980) Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. Arch Intern Med 140: 1201","journal-title":"Arch Intern Med"},{"key":"CR14","first-page":"55","volume":"41","author":"RB Jones","year":"1981","unstructured":"Jones RB, Collins JM, Myers CE, Brooks AE, Hubbard SM, Balow JE, Brennan MF, Dedrick RL, DeVita VT (1981) High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Res 41: 55","journal-title":"Cancer Res"},{"key":"CR15","first-page":"157","volume":"66","author":"CL Litterst","year":"1982","unstructured":"Litterst CL, Collins JM, Lowe MC, Arnold ST, Powell DM, Guarino AM (1982) Local and systemic toxicity resulting from large-volume ip administration of doxorubicin in the rat. Cancer Treat Rep 66: 157","journal-title":"Cancer Treat Rep"},{"key":"CR16","first-page":"593","volume":"9","author":"F Marechal","year":"1989","unstructured":"Marechal F, Berthiot G, Kritly T, Legrand MG, Deltour G, Cattan A (1989) Analysis of CA-125 levels in the sera of patients with non-ovarian carcinomas and non-malignant diseases. Anticancer Res 9: 593","journal-title":"Anticancer Res"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0305-7372(86)90007-1","volume":"13","author":"M Markman","year":"1986","unstructured":"Markman M (1986) Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity. Cancer Treat Rev 13: 219","journal-title":"Cancer Treat Rev"},{"key":"CR18","first-page":"49","volume":"2","author":"M Markman","year":"1989","unstructured":"Markman M, Kelsen D (1989) Intraperitoneal cisplatin and mitomycin as treatment for malignant peritoneal mesothelioma. Reg Cancer Treat 2: 49","journal-title":"Reg Cancer Treat"},{"key":"CR19","first-page":"445","volume":"162","author":"M Markman","year":"1986","unstructured":"Markman M, Cleary S, Howell SB, Lucas WE (1986) Complications of extensive adhesion formation after intraperitoneal chemotherapy. Surg Gynecol Obstet 162: 445","journal-title":"Surg Gynecol Obstet"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1200\/JCO.1990.8.1.146","volume":"8","author":"M Markman","year":"1990","unstructured":"Markman M, George M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL (1990) Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer. J Clin Oncol 8: 146","journal-title":"J Clin Oncol"},{"key":"CR21","first-page":"41","volume":"6","author":"JG McVie","year":"1987","unstructured":"McVie JG, Rodenhuis S, Dubbelman R, Varossiau FJ, Bokkel Huinink WW ten (1987) Clinical pharmacokinetics of intraperitoneal mitoxantrone in ovarian cancer. Proc Am Soc Clin Oncol 6: 41","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl 4","key":"CR22","first-page":"27","volume":"15","author":"BJ Monk","year":"1988","unstructured":"Monk BJ, Surwit EA, Alberts DS, Graham V (1988) Intraperitoneal mitomycin C in the treatment of peritoneal carcinomatosis following second-look surgery. Semin Oncol 15 [Suppl 4]: 27","journal-title":"Semin Oncol"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5694\/j.1326-5377.1989.tb136455.x","volume":"150","author":"AW Musk","year":"1989","unstructured":"Musk AW, Dolin PJ, Armstong BK, Ford JM, Klerk NH de, Hobbs MS (1989) The incidence of malignant mesothelioma in Australia, 1947?1980. Med J Aust 150: 242","journal-title":"Med J Aust"},{"key":"CR24","first-page":"4265","volume":"42","author":"RF Ozols","year":"1982","unstructured":"Ozols RF, Young RC, Speyer JL, Sugarbaker PH, Greene R, Jenkins J, Myers CE (1982) Phase I and pharmacological studies of Adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 42: 4265","journal-title":"Cancer Res"},{"key":"CR25","first-page":"205","volume":"69","author":"GE Pfeifle","year":"1985","unstructured":"Pfeifle GE, Howell SB, Markman M (1985) Intracavitary cisplatin chemotherapy for mesothelioma. Cancer Treat Rep 69: 205","journal-title":"Cancer Treat Rep"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archsurg.1988.01400300109019","volume":"123","author":"W Plaus","year":"1988","unstructured":"Plaus W (1988) Peritoneal mesothelioma. Arch Surg 123: 763","journal-title":"Arch Surg"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00172019","volume":"4","author":"JD Roberts","year":"1986","unstructured":"Roberts JD, Newman RA, Kimberly PJ, Hacker MP (1986) Regional fibrosis after intraperitoneal administration of mafosfamide. Invest New Drugs 4: 61","journal-title":"Invest New Drugs"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0305-7372(83)90008-7","volume":"10","author":"IE Smith","year":"1983","unstructured":"Smith IE (1983) Mitoxantrone (novantrone): a review of experimental and early clinical studies. Cancer Treat Rev 10: 103","journal-title":"Cancer Treat Rev"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/1097-0142(19890315)63:6<1084::AID-CNCR2820630608>3.0.CO;2-U","volume":"63","author":"KS Sridhar","year":"1989","unstructured":"Sridhar KS, Hussein AM, Feun LG, Zubrod CG (1989) Activity of pirarubicin (4?-0-tetrahydropyranyladriamycin) in malignant mesothelioma. Cancer 63: 1084","journal-title":"Cancer"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/0014-2964(76)90010-4","volume":"12","author":"H St\u00e4helin","year":"1976","unstructured":"St\u00e4helin H (1976) Delayed toxicity of epipodophyllotoxin derivates (VM 26 and VP 16-213) due to local effect. Eur J Cancer 12: 925","journal-title":"Eur J Cancer"},{"key":"CR31","first-page":"274","volume":"7","author":"L Weismann","year":"1988","unstructured":"Weismann L, Osteen R, Corson J, Herman T, Antman KH (1988) Combined modality therapy for intraperitoneal mesothelioma. Proc Am Soc Clin Oncol 7: 274","journal-title":"Proc Am Soc Clin Oncol"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2214\/ajr.138.3.531","volume":"138","author":"NO Whitley","year":"1982","unstructured":"Whitley NO, Brenner DE, Antman KH, Grant D, Aisner J (1982) CT of peritoneal mesothelioma: analysis of eight cases. AJR 138: 531","journal-title":"AJR"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00686012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00686012\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00686012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T11:12:10Z","timestamp":1585998730000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00686012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1992]]}},"alternative-id":["BF00686012"],"URL":"https:\/\/doi.org\/10.1007\/bf00686012","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992]]}}}